Use of leflunomide for inhibiting tumor necrosis factor alpha

Details Use of leflunomide for inhibiting tumor necrosis factor alpha Use of leflunomide for inhibiting tumor necrosis factor alpha

1995-03-28

1996-08-20

Goldberg, Jerome D.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

A61K 3142

Patent

active

055479707

ABSTRACT:
N-(4-Trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide is an effective compound for preventing and treating disorders in which tumor necrosis factor alpha is involved. It is used as a pharmaceutical.

REFERENCES:
patent: 4351841 (1982-09-01), Kammerer et al.
patent: 4965276 (1990-10-01), Bartlett et al.
T. Mattar et al., "Effects of Leflunomide (HWA 486) on Mediators of . . . ", Immunobiology, 178(1-2):156 (1988).
T. Zielinski et al., "Effects of Leflunomide (HWA 486) on Cell Cycle . . . ", Immunobiology, 186(1-2):113 (1992).
T. Smith-Oliver et al., "Elevated Levels of TNF in the Joints of . . . ", Cytokine, 5(4):298-304 (1993).
T. Zielinski et al., "Effects of Leflunomide (HWA 486) on Expression . . . ", Agent Actions, 38 (1993).
T. Mattar et al., "Inhibition of the Epidermal Growth Factor Receptor . . . ", Fed. of European Biochemical Soc. 334(2):161-164 (1993).
Bartlett et al., "Leflunomide (HWA 486), A Novel Immunomodulating Compound For The Treatment Of Autoimmune Disorders And Reactions Leading to Transplantation Rejection", Agents and Actions, 32:10-21 (1991).
Axton et al., "Novel Immunosuppressive Butenamides", J. Chem. Soc. Perkin Trans., 1:2203-2213 (1992).
Vilcek et al., "Tumor Necrosis Factor", J. Biol. Chem., 266(12):7313-7316 (1991).
Bevilacqua et al., "Endothelial Leukocyte Adhesion Molecule 1: An Inducible Receptor For Neutrophils Related to Complement Regulatory Proteins And Lectins", Science 243:1160-1164 (1989).
Tracey et al., "Shock And Tissue Injury Induced By Recombinant Human Cachectin", Science, 234:470-474 (1986).
Waage et al., "Association Between Tumour Necrosis Factor In Serum And Fatal Outcome In Patients With Meningococcal Disease", Lancet 1:355-357 (1987).
Lahdevirta et al., "Elevated Levels of Circulating Cachectin/Tumor Necrosis Factor in Patients With Acquired Immunodeficiency Syndrome", Am. J. Med., 85:289-291 (1988).
Balkwill et al., "Evidence For Tumour Necrosis Factor/Cachetin Production In Cancer", Lancet 2:1229-1232 (1987).
Blanchard et al., "The Induction Of Tumour Necrosis Factor (TNF) In Murine Lung Tissue During Infection with Legionella Pneumophila: A Potential Protective Role", Lymphokine Res. 6:1421 (1987).
Erroi et al., "The Pneumotoxicant Paraquat Potentiates IL-1 and TNF Production By Human Mononuclear Cells", Agents Actions, 36:66-69 (1992).
Mustafa et al., "Correlation Of Interleukin-1.beta. And Cachectin Concentrations In Cerebrospinal Fluid And Outcome From Bacterial Meningitis", J. Pediat., 115:208-213 (1989).
SCRIP, 1713:15 (1992).

Affiliated with

Also associated with

Rating

Use of leflunomide for inhibiting tumor necrosis factor alpha does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of leflunomide for inhibiting tumor necrosis factor alpha, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of leflunomide for inhibiting tumor necrosis factor alpha will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2331004